Phase 2 results with Wave Life Sciences' Duchenne muscular dystrophy candidate WVE-N531 pushed the company's share price to its highest level in a year and could lead to discussions with regulators ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback